Step Pharma Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Later Stage VC
- (In Progress)
- Latest Deal Amount
-
$10M
- Investors
-
13
Step Pharma General Information
Description
Developer of proprietary small molecule therapeutics designed for the treatment of autoimmune diseases. The company's therapeutics use a novel class of oral nucleotide synthesis inhibitors that can target CTPS1 (cytidine triphosphate synthase 1) to induce selective modulation of specific immune cell populations such as T and B cells, translating to better efficacy and an improved therapeutic index, enabling healthcare providers to properly treat autoimmune diseases.
Contact Information
Website
www.step-ph.comCorporate Office
- 15 Rue Louis and Auguste Lumière
- Technoparc du Pays-de-Gex
- 01630 Saint-Genis-Pouilly
- France
Corporate Office
- 15 Rue Louis and Auguste Lumière
- Technoparc du Pays-de-Gex
- 01630 Saint-Genis-Pouilly
- France
Step Pharma Timeline
Step Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Later Stage VC | 19-Feb-2026 | $10M | In Progress | Clinical Trials - Phase 1 | ||
| 12. Accelerator/Incubator | 19-Feb-2026 | Completed | Clinical Trials - Phase 1 | |||
| 11. Accelerator/Incubator | 01-Jan-2026 | Completed | Clinical Trials - Phase 1 | |||
| 10. Later Stage VC (Series C) | 15-Oct-2025 | Completed | Clinical Trials - Phase 1 | |||
| 9. Accelerator/Incubator | 01-Jan-2024 | Completed | Clinical Trials - Phase 1 | |||
| 8. Secondary Transaction - Private | 01-Jul-2021 | Completed | Pre-Clinical Trials | |||
| 7. Later Stage VC (Series B) | 24-Mar-2021 | Completed | Pre-Clinical Trials | |||
| 6. Early Stage VC | 16-Dec-2018 | Completed | Pre-Clinical Trials | |||
| 5. Early Stage VC (Series A) | 21-Nov-2017 | $16.9M | $21.2M | Completed | Startup | |
| 4. Early Stage VC | 28-Jul-2015 | $830K | $4.22M | Completed | Startup |
Step Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| C shares | ||||||||
| BSA-T4 | ||||||||
| BSA-T3 | ||||||||
| BSA-T2 | ||||||||
| ADP B | ||||||||
| Category B Preference | ||||||||
| Ordinary | ||||||||
| Series A | ||||||||
| Series A | 2,935,873 | $0.117118 | $2.34 | $2.34 | 1x | $2.34 | 7.05% | |
| Ordinary | 1,250,000 | $0.117118 | $2.34 | $2.34 | 1x | $2.34 | 3% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Step Pharma Comparisons
Industry
Financing
Details
Step Pharma Competitors (47)
One of Step Pharma’s 47 competitors is Kite Pharma, a Formerly VC-backed company based in Santa Monica, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Noveome Biotherapeutics | Venture Capital-Backed | Pittsburgh, PA | ||||
| Carisma Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Adimab | Venture Capital-Backed | Lebanon, NH |
Step Pharma Patents
Step Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026027753-A1 | Ctps1 inhibitors for the treatment of myeloproliferative neoplasms | Pending | 02-Aug-2024 | ||
| WO-2024133721-A1 | Combinations of ctps1 inhibitor with iap inhibitor for use in the treatment of cancer | Inactive | 21-Dec-2022 | ||
| AU-2023411337-A1 | Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer | Pending | 21-Dec-2022 | ||
| EP-4637770-A1 | Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer | Pending | 21-Dec-2022 | ||
| US-20260207590-A1 | Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer | Pending | 21-Dec-2022 | A61K31/506 |
Step Pharma Signals
Step Pharma Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| European Innovation Council | Accelerator/Incubator | Minority | ||
| La French Tech | Accelerator/Incubator | |||
| InnoBiologics | Venture Capital | Minority | ||
| V-Bio Ventures | Venture Capital | Minority | ||
| Matwin | Accelerator/Incubator |
Step Pharma FAQs
-
When was Step Pharma founded?
Step Pharma was founded in 2014.
-
Where is Step Pharma headquartered?
Step Pharma is headquartered in Saint-Genis-Pouilly, France.
-
What is the size of Step Pharma?
Step Pharma has 12 total employees.
-
What industry is Step Pharma in?
Step Pharma’s primary industry is Drug Discovery.
-
Is Step Pharma a private or public company?
Step Pharma is a Private company.
-
What is Step Pharma’s current revenue?
The current revenue for Step Pharma is .
-
How much funding has Step Pharma raised over time?
Step Pharma has raised $115M.
-
Who are Step Pharma’s investors?
European Innovation Council, La French Tech, InnoBiologics, V-Bio Ventures, and Matwin are 5 of 13 investors who have invested in Step Pharma.
-
Who are Step Pharma’s competitors?
Kite Pharma, Noveome Biotherapeutics, Carisma Therapeutics, Adaptimmune Therapeutics, and Adimab are some of the 47 competitors of Step Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process